Cited 39 times in
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2020-04-13T16:42:46Z | - |
dc.date.available | 2020-04-13T16:42:46Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175476 | - |
dc.description.abstract | Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC. Methods: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC. Eligible patients must have advanced clear cell RCC and must not have received any prior systemic anticancer therapy. The primary end point is progression-free survival; secondary end points include objective response rate, overall survival, safety, health-related quality of life and pharmacokinetics. Biomarker evaluations are included as exploratory end points. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Viktor Grünwald | - |
dc.contributor.googleauthor | Thomas Powles | - |
dc.contributor.googleauthor | Toni K Choueiri | - |
dc.contributor.googleauthor | Thomas E Hutson | - |
dc.contributor.googleauthor | Camillo Porta | - |
dc.contributor.googleauthor | Masatoshi Eto | - |
dc.contributor.googleauthor | Cora N Sternberg | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Cixin S He | - |
dc.contributor.googleauthor | Corina E Dutcus | - |
dc.contributor.googleauthor | Alan Smith | - |
dc.contributor.googleauthor | Lea Dutta | - |
dc.contributor.googleauthor | Kalgi Mody | - |
dc.contributor.googleauthor | Robert J Motzer | - |
dc.identifier.doi | 10.2217/fon-2018-0745 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.subject.keyword | everolimus | - |
dc.subject.keyword | first-line treatment | - |
dc.subject.keyword | immuno-oncology | - |
dc.subject.keyword | lenvatinib | - |
dc.subject.keyword | pembrolizumab | - |
dc.subject.keyword | renal cell carcinoma | - |
dc.subject.keyword | sunitinib | - |
dc.subject.keyword | tyrosine kinase inhibitor | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 929 | - |
dc.citation.endPage | 941 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.15(9) : 929-941, 2019 | - |
dc.identifier.rimsid | 64422 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.